Comparative Pharmacology
Head-to-head clinical analysis: NIMBEX versus SYNCURINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NIMBEX versus SYNCURINE.
NIMBEX vs SYNCURINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, blocking neurotransmission and inducing muscle relaxation.
Competitive antagonist of nicotinic acetylcholine receptors at the neuromuscular junction, blocking neurotransmission and causing skeletal muscle paralysis.
0.15-0.2 mg/kg IV bolus for intubation; maintenance infusion 1-2 mcg/kg/min (initial) adjusted to effect.
0.1-0.2 mg/kg IV bolus for paralysis, repeat 0.05-0.1 mg/kg as needed; maintenance infusion 0.5-1.5 mcg/kg/min IV.
None Documented
None Documented
Terminal elimination half-life approximately 20-30 minutes in healthy adults; prolonged in hepatic or renal impairment.
Terminal half-life: 2-5 hours (prolonged with renal impairment; up to 10 hours in severe impairment)
Primarily renal (80% as unchanged drug and metabolites); biliary/fecal excretion accounts for <20%.
Primarily renal excretion (50-70% unchanged drug), with biliary/fecal elimination (10-20%)
Category C
Category C
Neuromuscular Blocking Agent
Neuromuscular Blocking Agent